Takeda Pharmaceutical has been noted as a top Japanese pharmaceutical stock for 2025. Following a complete share buyback resulting in the acquisition of 11.8 million shares, the company's leadership has undergone a shuffle with CEO Christophe Weber set to step down. Nevertheless, strong earnings and an improved guidance indicate a robust business core, potentially proving the company to be undervalued. Multiple rating and target raises further support this, with individual investors owning the majority of the shares. Several noteworthy events include the first-ever treatment for ALGS and PFIC, the continuation of a stock compensation plan and a significant top-line growth driver. The company has also launched a dengue prevention programme across India under USAID. Despite this, investors should be mindful of the high dividend yield hiding potential pitfalls for US investors. The pharmaceutical company underwent a merger and announced a subsidiary liquidation plan while unveiling an employee incentive plan in a bid for continued progress. Their pipeline is promising, but still under development. It’s also worth noting that shares did undergo a -6.19% decrease over 4 weeks.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Fri, 25 Apr 2025 17:28:11 GMT -
Rating 5
- Innovation 0
- Information 7
- Rumor -3
